Akebia Therapeutics secures a $60 million loan from Symbiotic Capital to repay a BlackRock facility and access additional funding.
Quiver AI Summary
Akebia Therapeutics, Inc. announced the closing of a senior secured term loan facility with Symbiotic Capital, featuring an initial tranche of $60 million, which has been fully funded and used to repay a $55 million loan from BlackRock. The facility also includes the potential for an additional $80 million in financing at Symbiotic Capital's discretion. The loan has a 60-month term with an interest-only period and a variable interest rate. Akebia's leadership expressed enthusiasm about the partnership with Symbiotic, which enhances their operational flexibility and provides non-dilutive capital to support their strategic initiatives and a projected cash runway of at least two years.
Potential Positives
- Initial $60 million tranche fully funded, allowing for the complete repayment of the $55 million BlackRock loan facility, enhancing financial stability.
- Access to an incremental tranche of up to $80 million in term loan financing, providing potential for further operational flexibility and capital without dilution.
- Reaffirmation of a cash runway guidance of at least two years, indicating a strong financial outlook and ability to support ongoing initiatives.
- Strategic partnership with Symbiotic Capital, bringing expertise in healthcare financing to support Akebia's growth and business strategy execution.
Potential Negatives
- Akebia's reliance on the new loan facility to repay a significant existing debt to BlackRock may indicate financial instability or cash flow issues.
- The variable interest rate of the new loan facility, linked to WSJ Prime plus 4.5% or a minimum of 11.5%, poses a risk of increasing financial costs as interest rates rise.
FAQ
What is the Symbiotic Loan Facility?
The Symbiotic Loan Facility is a senior secured term loan arrangement with an initial tranche of $60 million and an option for up to $80 million.
When did the Symbiotic Loan Facility close?
The Symbiotic Loan Facility closed on November 12, 2026.
How will Akebia use the loan proceeds?
Akebia used the initial tranche to fully repay its $55 million loan facility with BlackRock.
What is the maturity period of the loan facility?
The loan facility has a maturity period of 60 months, with principal due at maturity.
Who is Akebia Therapeutics?
Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of people impacted by kidney disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKBA Insider Trading Activity
$AKBA insiders have traded $AKBA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $AKBA stock by insiders over the last 6 months:
- ERIK OSTROWSKI (SVP, CFO, CBO & Treasurer) sold 56,019 shares for an estimated $62,181
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AKBA Hedge Fund Activity
We have seen 79 institutional investors add shares of $AKBA stock to their portfolio, and 104 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 7,358,904 shares (+410.5%) to their portfolio in Q2 2026, for an estimated $8,389,150
- ACADIAN ASSET MANAGEMENT LLC added 4,965,496 shares (+124.0%) to their portfolio in Q3 2026, for an estimated $4,568,256
- JACOBS LEVY EQUITY MANAGEMENT, INC added 3,843,357 shares (+894.5%) to their portfolio in Q2 2026, for an estimated $4,381,426
- BANK OF AMERICA CORP /DE/ removed 2,304,612 shares (-83.4%) from their portfolio in Q2 2026, for an estimated $2,627,257
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 2,300,438 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $2,116,402
- JANE STREET GROUP, LLC removed 1,456,674 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,660,608
- TWO SIGMA INVESTMENTS, LP added 1,138,872 shares (+87.8%) to their portfolio in Q2 2026, for an estimated $1,298,314
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AKBA Analyst Ratings
Wall Street analysts have issued reports on $AKBA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2026
- BTIG issued a "Buy" rating on 11/05/2026
- WestPark Capital issued a "Buy" rating on 09/08/2026
To track analyst ratings and price targets for $AKBA, check out Quiver Quantitative's $AKBA forecast page.
$AKBA Price Targets
Multiple analysts have issued price targets for $AKBA recently. We have seen 4 analysts offer price targets for $AKBA in the last 6 months, with a median target of $3.5.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $4.0 on 11/06/2026
- Julian Harrison from BTIG set a target price of $3.0 on 11/05/2026
- Ed Arce from WestPark Capital set a target price of $4.5 on 09/08/2026
- Roanna Ruiz from Leerink Partners set a target price of $1.0 on 08/07/2026
Full Release
Initial $60 million tranche fully funded, proceeds of which were used to fully repay $55 million BlackRock loan facility
Incremental tranche of up to $80 million in term loan financing available at Symbiotic Capital’s discretion
WALTHAM, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has entered into a senior secured term loan facility with Symbiotic Capital (the “Symbiotic Loan Facility”). The Symbiotic Loan Facility consists of an initial tranche of $60.0 million that was fully funded at closing and the ability to request up to an additional $80.0 million, which Symbiotic Capital may fund at its discretion.
The Symbiotic Loan Facility closed on November 12, 2026. Akebia used the proceeds from the initial tranche to repay in full its $55.0 million loan facility with BlackRock. The Symbiotic Loan Facility has a 60-month maturity, a 60-month interest-only period with principal due at maturity, and bears interest at a variable monthly interest rate equal to the greater of WSJ Prime plus 4.5% or 11.5%.
“We are very pleased to announce this financing which enhances our operational flexibility and gives us the potential to access additional non-dilutive capital to advance our strategic initiatives. Today we also reaffirm our cash runway guidance of at least two years,” said Erik Ostrowski, Akebia’s Chief Financial and Chief Business Officer. “We are excited to partner with Symbiotic Capital, whose deep expertise in healthcare financing makes them an ideal collaborator. We are also very appreciative of our partnership with BlackRock over the past several years.”
“Akebia has a portfolio of revenue-generating products and a pipeline focused on kidney disease, led by a management team with deep experience in the space,” said Chris York, Senior Managing Director at Symbiotic Capital. “We are pleased to provide this financing and look forward to supporting Akebia as it executes on its business strategy.”
Additional details of the loan agreement will be provided in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission (SEC) on November 16, 2026.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at
www.akebia.com
, which does not form a part of this release.
About Symbiotic Capital
Symbiotic Capital is a healthcare credit platform that brings together decades of experience across healthcare, finance, and entrepreneurship. Its integration into a global healthcare ecosystem empowers it to provide lending solutions to fuel the growth of established healthcare companies around the world.
Forward-Looking Statements
Statements in this press release regarding Akebia Therapeutics, Inc.'s (“Akebia's”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: the potential for Akebia to access up to an additional $80 million in incremental discretionary tranches of term loan financing under the Symbiotic Loan Facility; Akebia’s expectations and beliefs regarding the impact of the financing, including the extent to which it enhances its operational flexibility and the potential access to additional non-dilutive capital; Akebia’s ability to advance its strategic initiatives and execute on its business strategy; and Akebia’s beliefs and expectations regarding the sufficiency of, and the period in which Akebia expects to have, cash to fund its current operating plan.
The terms “intend,” “believe,” “designed,” “plan,” “goal,” “potential,” “anticipate,” “estimate,” “target,” “predict,” “expect,” “future,” “may,” “will,” “could,” “continue,” derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the potential therapeutic benefits, safety profile and effectiveness of Akebia's products and product candidates; risks and uncertainties related to Akebia's ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials, and the timing of such preclinical studies and clinical trials; the results of Akebia's preclinical studies and clinical trials, including that initial, preliminary, interim, or topline results do not necessarily predict final results and remain subject to final verification that may result in the final data being materially different from the initial data previously published; preclinical, clinical or retrospective data, analyses or results may not be replicated in, or predictive of, results of future preclinical or clinical data, analyses or results or that such analyses or results may not support further development of such product candidates; Akebia's ability to initiate and enroll patients in its clinical trials; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to Akebia's commercial products, including estimates regarding the potential market opportunity; the competitive landscape for Akebia's commercial products, including generic entrants and the timing thereof; Akebia's ability to obtain and maintain patent protection on its products and product candidates, and to successfully defend these patents against third-party challenges; Akebia's ability to attract and retain qualified personnel; Akebia's ability to achieve and maintain profitability and to maintain operating expenses consistent with its operating plan; Akebia's revenue and that its financial results from prior periods may not be indicative of future results; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; early termination of any of Akebia's collaborations; and changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs. Other risks and uncertainties include those identified under the heading “Risk Factors” in Akebia's most recent Quarterly Report on Form 10-Q filed with the SEC, and other filings that Akebia may make with the SEC in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.
Akebia Therapeutics ® and Vafseo ® are registered trademarks of Akebia Therapeutics, Inc. and its affiliates.
Akebia Therapeutic Contact
Mercedes Carrasco
[email protected]